Up-regulation of Cell Cycle Arrest Protein BTG2 Correlates with Increased Overall Survival in Breast Cancer, As Detected by Immunohistochemistry Using Tissue Microarray

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Jun 18

PMID 20553615

Citations 18

Authors

Elin Mollerstrom

Aniko Kovacs

Kristina Lovgren

Szilard Nemes

Ulla Delle

Anna Danielsson

Toshima Parris

Donal J Brennan

Karin Jirstrom

Per Karlsson

Khalil Helou

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have shown that the ADIPOR1, ADORA1, BTG2 and CD46 genes differ significantly between long-term survivors of breast cancer and deceased patients, both in levels of gene expression and DNA copy numbers. The aim of this study was to characterize the expression of the corresponding proteins in breast carcinoma and to determine their correlation with clinical outcome.

Methods: Protein expression was evaluated using immunohistochemistry in an independent breast cancer cohort of 144 samples represented on tissue microarrays. Fisher's exact test was used to analyze the differences in protein expression between dead and alive patients. We used Cox-regression multivariate analysis to assess whether the new markers predict the survival status of the patients better than the currently used markers.

Results: BTG2 expression was demonstrated in a significantly lower proportion of samples from dead patients compared to alive patients, both in overall expression (P = 0.026) and cell membrane specific expression (P = 0.013), whereas neither ADIPOR1, ADORA1 nor CD46 showed differential expression in the two survival groups. Furthermore, a multivariate analysis showed that a model containing BTG2 expression in combination with HER2 and Ki67 expression along with patient age performed better than a model containing the currently used prognostic markers (tumour size, nodal status, HER2 expression, hormone receptor status, histological grade, and patient age). Interestingly, BTG2 has previously been described as a tumour suppressor gene involved in cell cycle arrest and p53 signalling.

Conclusions: We conclude that high-level BTG2 protein expression correlates with prolonged survival in patients with breast carcinoma.

Citing Articles

Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules.

Chen L, Singha Roy S, Jadhav A, Wang W, Chen P, Bishop T ACS Chem Biol. 2024; 19(9):1918-1929.

PMID: 39250704 PMC: 11421428. DOI: 10.1021/acschembio.4c00438.

Construction and analysis of lncRNA-associated ceRNA network identified potential prognostic biomarker in gastric cancer.

Peng J, Zhu Y, Dong X, Mao X, Lou Y, Mu Y Transl Cancer Res. 2022; 8(4):1116-1128.

PMID: 35116854 PMC: 8798625. DOI: 10.21037/tcr.2019.06.32.

A conserved motif in human BTG1 and BTG2 proteins mediates interaction with the poly(A) binding protein PABPC1 to stimulate mRNA deadenylation.

Amine H, Ripin N, Sharma S, Stoecklin G, Allain F, Seraphin B RNA Biol. 2021; 18(12):2450-2465.

PMID: 34060423 PMC: 8632095. DOI: 10.1080/15476286.2021.1925476.

MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells.

Zhu B, Chen W, Fu Y, Cui X, Jin L, Chao J Onco Targets Ther. 2020; 13:6873-6884.

PMID: 32764979 PMC: 7368588. DOI: 10.2147/OTT.S256153.

Translational downregulation of Twist1 expression by antiproliferative gene, B-cell translocation gene 2, in the triple negative breast cancer cells.

Devanand P, Sundaramoorthy S, Ryu M, Jayabalan A, Ohn T, Lim I Cell Death Dis. 2019; 10(6):410.

PMID: 31138781 PMC: 6538657. DOI: 10.1038/s41419-019-1640-z.

References

Kawakubo H, Brachtel E, Hayashida T, Yeo G, Kish J, Muzikansky A . Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 2006; 66(14):7075-82. DOI: 10.1158/0008-5472.CAN-06-0379. View

Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H . Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18(7):1133-44. DOI: 10.1093/annonc/mdm271. View

Lim I, Lee M, Lee S, Kim N, Jou I, Seo J . Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines. J Cancer Res Clin Oncol. 1995; 121(5):279-84. DOI: 10.1007/BF01209594. View

Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi F, Barnas C . BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog. 2000; 27(2):57-64. View

Heymans M, van Buuren S, Knol D, van Mechelen W, de Vet H . Variable selection under multiple imputation using the bootstrap in a prognostic study. BMC Med Res Methodol. 2007; 7:33. PMC: 1945032. DOI: 10.1186/1471-2288-7-33. View

Lim Y, Park T, Lim I . B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage. J Biol Chem. 2008; 283(48):33110-8. PMC: 2662249. DOI: 10.1074/jbc.M804255200. View

Kaklamani V, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H . Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008; 68(9):3178-84. PMC: 2685173. DOI: 10.1158/0008-5472.CAN-08-0533. View

Montagnoli A, Guardavaccaro D, Starace G, Tirone F . Overexpression of the nerve growth factor-inducible PC3 immediate early gene is associated with growth inhibition. Cell Growth Differ. 1996; 7(10):1327-36. View

Melamed J, Kernizan S, Walden P . Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell. 2002; 34(1):28-32. DOI: 10.1054/tice.2001.0220. View

10.

Islaih M, Halstead B, Kadura I, Li B, Reid-Hubbard J, Flick L . Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res. 2005; 578(1-2):100-16. DOI: 10.1016/j.mrfmmm.2005.04.012. View

11.

Gehan E . A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965; 52:203-23. View

12.

Ryden L, Landberg G, Stal O, Nordenskjold B, Ferno M, Bendahl P . HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat. 2007; 109(2):351-7. DOI: 10.1007/s10549-007-9660-2. View

13.

Madjd Z, Durrant L, Pinder S, Ellis I, Ronan J, Lewis S . Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?. Cancer Immunol Immunother. 2004; 54(2):149-56. PMC: 11034299. DOI: 10.1007/s00262-004-0590-0. View

14.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

15.

Kawakubo H, Carey J, Brachtel E, Gupta V, Green J, Walden P . Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene. 2004; 23(50):8310-9. DOI: 10.1038/sj.onc.1208008. View

16.

Boiko A, Porteous S, Razorenova O, Krivokrysenko V, Williams B, Gudkov A . A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 2006; 20(2):236-52. PMC: 1356114. DOI: 10.1101/gad.1372606. View

17.

Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F, Puisieux A . BTG2, its family and its tutor. Bull Cancer. 2004; 91(7-8):E242-53. View

18.

Coleman M, Quaresma M, Berrino F, Lutz J, De Angelis R, Capocaccia R . Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9(8):730-56. DOI: 10.1016/S1470-2045(08)70179-7. View

19.

Naderi A, Teschendorff A, Barbosa-Morais N, Pinder S, Green A, Powe D . A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2006; 26(10):1507-16. DOI: 10.1038/sj.onc.1209920. View

20.

Heagerty P, Zheng Y . Survival model predictive accuracy and ROC curves. Biometrics. 2005; 61(1):92-105. DOI: 10.1111/j.0006-341X.2005.030814.x. View